Liu, Q. et al. 2023. Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer. Clinics. 78, (May 2023), 100291. DOI:https://doi.org/10.1016/.